netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US

ProAxsis to Present at 2017 British Thoracic Society Winter Meeting

Dec 5, 2017
-
News, ProAxsis

London, UK – 05 December 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes the announcement by its portfolio company, ProAxsis, which will have its ProteaseTag® technology featured at the 2017 British Thoracic Society Winter Meeting on the 7th and 8th of December.

The first presentation will cover lung patient care: “NEATstik® – A Novel Point-of-Care Test for the Measurement of Active Neutrophil Elastase in Patients with Respiratory Disease” by Dr Kelly Moffitt, COO of ProAxsis on the 7thof December. The second presentation will cover the clinical implications of cystic fibrosis: “It is possible to detect active neutrophil elastase in exhaled breath condensate of patients with cystic fibrosis” by Dr Claire Edmondson, NHLI Imperial College and Royal Brompton Hospital, London on the 8th December.

 

NetScientific holds a 57% stake on a fully diluted basis in ProAxsis.

 

The full text of the announcement from ProAxsis can be found below.

 

 

#  #  #

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800
Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson /

Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com
Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison
Tel: +44 (0) 20 7710 7600
ProAxsis to Present at 2017 British Thoracic Society Winter Meeting

Date: December 05, 2017

ProAxsis’ ProteaseTag® technology will again be featured at the Winter meeting of the British Thoracic Society, which takes place between December 6th-8th at the Queen Elizabeth II Conference Centre, in London.  Further details of the abstracts accepted for presentation by the conference review committee are detailed below:

 

NEATstik® – A Novel Point-of-Care Test for the Measurement of Active Neutrophil Elastase in Patients with Respiratory Disease (Poster no. 116).

Presenting author: Dr Kelly Moffitt (ProAxsis Limited)

Session – Infected lung: from bench to bedside

Thursday 7th December

 

It is possible to detect active neutrophil elastase in exhaled breath condensate of patients with cystic fibrosis (Poster no. 249).

Presenting author: Dr Claire Edmondson (NHLI Imperial College and Royal Brompton Hospital, London)

Session – Clinical implications of cystic fibrosis

Friday 8th December

 

Dr David Ribeiro, CEO of ProAxsis, said: “The BTS stated goal is to improve standards of care for people who have respiratory diseases, and the organisation currently has more than 3400 members.  Having recently registered a European CE Mark for our rapid neutrophil elastase point-of-care test, NEATstik®, ProAxsis is delighted to be sharing the first real world data for this exciting new product at the BTS meeting.”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies.  The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com.

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

About ProAxsis Limited:

 

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases. Its first immunoassay measures neutrophil elastase, a leading indicator of infection and inflammation in patients with Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis, and an important drug target. The rapid and easy-to-use tests being developed by ProAxsis incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags® provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.

ProAxsis is part of the NetScientific Group and is one of the Group’s core portfolio companies.  The company is also supported by QUBIS, the commercialisation arm of Queens University.

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
NetScientific CEO to Present at Shares Investor Evening at 19:30 on the 14th December 2017
NEXT POST →
NetScientific CEO to Present at Proactive Investors at 18:30 on the 7th December 2017

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
Copyright
Terms of Use
ProAxsis to Present at 2017 British Thoracic Society Winter Meeting - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT